Clinical assessment of a trimethoprim-sulfamethopyrazine combination (Kelfiprim) in lower respiratory tract infections.

Abstract

The new combination of trimethoprim 250 mg and sulfamethopyrazine 200 mg was used in fourteen out-patients and eighteen in-patients with acute exacerbation of chronic bronchitis, pneumonia or bronchopneumonia due to sensitive bacteria. The drug was given for 1 to 2 weeks as one capsule daily (following a double loading dose on the first day), and ampicillin, 500 mg capsules q.i.d., was administered to another group of eleven in-patients for comparison. Overall results, based on clinical, radiological and laboratory findings, were excellent or good in 85% and 67%, respectively, of out- and in-patients receiving the combination drug; definite failures were one out of fourteen and two out of eighteen cases, and the remainder were assessed as fair. In three out of thirty-two patients mild to moderate gastro-intestinal side-effects were observed during treatment. The drug compared favourably to ampicillin for both effectiveness and safety.

• Authors: H Harazim, M John, E Pandelitschka, H Bröll, G Jackwerth
• Journal: The Journal of international medical research (J Int Med Res) Vol. 11 Issue 4 Pg. 197-204 ( 1983) ISSN: 0300-0605 [Print] England
• PMID: 6352364 (Publication Type: Clinical Trial, Comparative Study, Journal Article)

Chemical References

• Drug Combinations
• Sulfanilamides
• kelfiprim
• Ampicillin
• Trimethoprim
• Sulfalene

Topics

• Adult
• Aged
• Ampicillin (therapeutic use)
• Bronchitis (drug therapy)
• Bronchopneumonia (drug therapy)
• Clinical Trials as Topic
• Double-Blind Method
• Drug Combinations (therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Pneumonia (drug therapy)
• Random Allocation
• Respiratory Tract Infections (drug therapy)
• Sulfalene (therapeutic use)
• Sulfanilamides (therapeutic use)
• Trimethoprim (therapeutic use)